CEREVEL THERAPEUTICS HOLDING (CERE) Stock Price & Overview
NASDAQ:CERE • US15678U1280
Current stock price
The current stock price of CERE is 44.96 USD. Today CERE is up by 0.74%. In the past month the price increased by 9.05%. In the past year, price increased by 100.09%.
CERE Key Statistics
- Market Cap
- 8.191B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.73
- Dividend Yield
- N/A
CERE Stock Performance
CERE Stock Chart
CERE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CERE. When comparing the yearly performance of all stocks, CERE is one of the better performing stocks in the market, outperforming 96.77% of all stocks.
CERE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CERE. While CERE seems to be doing ok healthwise, there are quite some concerns on its profitability.
CERE Earnings
CERE Forecast & Estimates
14 analysts have analysed CERE and the average price target is 44.27 USD. This implies a price decrease of -1.54% is expected in the next year compared to the current price of 44.96.
CERE Groups
Sector & Classification
CERE Financial Highlights
Over the last trailing twelve months CERE reported a non-GAAP Earnings per Share(EPS) of -2.73. The EPS decreased by -7.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.85% | ||
| ROE | -81.58% | ||
| Debt/Equity | 0.6 |
CERE Ownership
CERE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 362.599B | ||
| AMGN | AMGEN INC | 15.24 | 187.489B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 170.335B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 115.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.479B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.4B | ||
| INSM | INSMED INC | N/A | 29.315B | ||
| NTRA | NATERA INC | N/A | 27.677B | ||
| BIIB | BIOGEN INC | 11.29 | 26.631B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 22.979B | ||
| MRNA | MODERNA INC | N/A | 20.292B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.981B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CERE
Company Profile
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 355 full-time employees. The company went IPO on 2020-06-05. The firm is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. The company focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Company Info
IPO: 2020-06-05
CEREVEL THERAPEUTICS HOLDING
222 Jacobs Street, Suite 200
Cambridge MASSACHUSETTS 02116 US
CEO: N. Anthony Coles
Employees: 355
Phone: 18443042048
CEREVEL THERAPEUTICS HOLDING / CERE FAQ
Can you describe the business of CEREVEL THERAPEUTICS HOLDING?
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 355 full-time employees. The company went IPO on 2020-06-05. The firm is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. The company focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Can you provide the latest stock price for CEREVEL THERAPEUTICS HOLDING?
The current stock price of CERE is 44.96 USD. The price increased by 0.74% in the last trading session.
Does CERE stock pay dividends?
CERE does not pay a dividend.
How is the ChartMill rating for CEREVEL THERAPEUTICS HOLDING?
CERE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for CEREVEL THERAPEUTICS HOLDING?
CEREVEL THERAPEUTICS HOLDING (CERE) will report earnings on 2024-10-30, before the market open.